[go: up one dir, main page]

MX2013006819A - Composicion antigenica de micobacteria. - Google Patents

Composicion antigenica de micobacteria.

Info

Publication number
MX2013006819A
MX2013006819A MX2013006819A MX2013006819A MX2013006819A MX 2013006819 A MX2013006819 A MX 2013006819A MX 2013006819 A MX2013006819 A MX 2013006819A MX 2013006819 A MX2013006819 A MX 2013006819A MX 2013006819 A MX2013006819 A MX 2013006819A
Authority
MX
Mexico
Prior art keywords
antigenic composition
mycobacterium
mycobacterium antigenic
composition
medicine
Prior art date
Application number
MX2013006819A
Other languages
English (en)
Other versions
MX344280B (es
Inventor
Dominique Ingrid Lemoine
Amina Laanan
Stephane Andre Georges Godart
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2013006819A publication Critical patent/MX2013006819A/es
Publication of MX344280B publication Critical patent/MX344280B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones inmunógenas que comprenden un antígeno relacionado con Rv1196, en donde la conductividad de la composición es de 13 mS/cm o menor, o la concentración de sales de la composición es de 130 mM o menor, y su uso en medicina.
MX2013006819A 2010-12-14 2011-12-14 Composicion antigenica de micobacteria. MX344280B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072817 WO2012080370A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (2)

Publication Number Publication Date
MX2013006819A true MX2013006819A (es) 2013-08-26
MX344280B MX344280B (es) 2016-12-09

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013006818A MX344706B (es) 2010-12-14 2011-12-14 Composición antigénica de micobacteria.
MX2013006819A MX344280B (es) 2010-12-14 2011-12-14 Composicion antigenica de micobacteria.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013006818A MX344706B (es) 2010-12-14 2011-12-14 Composición antigénica de micobacteria.

Country Status (33)

Country Link
US (5) US9352030B2 (es)
EP (4) EP3593813A1 (es)
JP (2) JP5951633B2 (es)
KR (3) KR101951894B1 (es)
CN (4) CN106822882A (es)
AR (1) AR084285A1 (es)
AU (2) AU2011343367B2 (es)
BR (2) BR112013014598A2 (es)
CA (2) CA2819298A1 (es)
CO (2) CO6751288A2 (es)
CY (1) CY1122187T1 (es)
DK (3) DK3023106T3 (es)
EA (2) EA027920B1 (es)
ES (3) ES2567190T3 (es)
HR (3) HRP20160606T1 (es)
HU (3) HUE027932T2 (es)
IL (2) IL226448A (es)
LT (1) LT3023106T (es)
ME (1) ME02380B (es)
MX (2) MX344706B (es)
MY (1) MY161412A (es)
PH (2) PH12013501204A1 (es)
PL (3) PL3023106T3 (es)
PT (2) PT3023106T (es)
RS (1) RS54687B1 (es)
SG (2) SG190937A1 (es)
SI (3) SI2651436T1 (es)
SM (1) SMT201600118B (es)
TW (1) TW201305192A (es)
UA (2) UA110806C2 (es)
UY (1) UY33802A (es)
WO (2) WO2012080369A1 (es)
ZA (2) ZA201304014B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006243357B2 (en) 2005-04-29 2012-03-15 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
EP2661253B1 (en) * 2011-01-04 2017-04-19 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2013104943A1 (en) 2012-01-12 2013-07-18 Archivel Farma, S.L. Mtb-c vaccine against asthma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015164675A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1025160B1 (fr) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa Nouveau procédé
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
US20210292395A1 (en) 2018-07-31 2021-09-23 Glaxosmithkline Biologicals Sa Antigen purification method
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN114466659A (zh) 2019-09-09 2022-05-10 葛兰素史克生物有限公司 免疫治疗组合物
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021224205A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4259814A2 (en) 2020-12-09 2023-10-18 GlaxoSmithKline Biologicals SA Modification of saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK2154248T3 (da) 1995-09-01 2012-01-30 Corixa Corp Forbindelser og fremgangsmåder til diagnose af tuberkulose
ATE323165T1 (de) 1995-09-01 2006-04-15 Corixa Corp Verbindungen und verfahren zur immuntherapie und diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
ATE261734T1 (de) * 1997-04-08 2004-04-15 Merck & Co Inc Stabilisierte humane papillomaviruszusammensetzungen
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
KR100692227B1 (ko) * 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7311922B1 (en) 1999-10-07 2007-12-25 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT1542732E (pt) 2000-06-20 2009-11-06 Corixa Corp Proteínas de fusão de mycobacterium tuberculosis
MXPA03000198A (es) 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2006243357B2 (en) 2005-04-29 2012-03-15 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
WO2008142133A1 (en) 2007-05-24 2008-11-27 Glaxosmithkline Biologicals S.A Lyophilised antigen composition
CN104645329A (zh) * 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
CA2819297A1 (en) 2012-06-21
KR20190022897A (ko) 2019-03-06
AU2011343368B2 (en) 2015-08-20
WO2012080369A1 (en) 2012-06-21
AU2011343367A1 (en) 2013-07-11
CN103249431A (zh) 2013-08-14
SI2651437T1 (sl) 2016-05-31
JP2014505036A (ja) 2014-02-27
CN103260642A (zh) 2013-08-21
MX2013006818A (es) 2013-08-26
EP3023106B1 (en) 2019-07-31
CO6751288A2 (es) 2013-09-16
HUE027932T2 (en) 2016-11-28
PL2651436T3 (pl) 2016-10-31
SI3023106T1 (sl) 2019-11-29
DK2651437T3 (en) 2016-05-02
US20190183998A1 (en) 2019-06-20
RS54687B1 (sr) 2016-08-31
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
US9352030B2 (en) 2016-05-31
JP2013545783A (ja) 2013-12-26
US20130280289A1 (en) 2013-10-24
US20180071378A1 (en) 2018-03-15
CN106822883A (zh) 2017-06-13
EA201390631A1 (ru) 2014-11-28
ZA201304014B (en) 2017-04-26
AU2011343368A1 (en) 2013-07-11
HRP20160606T1 (hr) 2016-07-01
CN103260642B (zh) 2018-03-16
IL226450A0 (en) 2013-07-31
WO2012080370A1 (en) 2012-06-21
BR112013014598A2 (pt) 2017-09-19
PT3023106T (pt) 2019-11-04
ES2574403T3 (es) 2016-06-17
BR112013014599A2 (pt) 2016-09-27
LT3023106T (lt) 2019-10-25
ES2748651T3 (es) 2020-03-17
PT2651436E (pt) 2016-06-08
US9730992B2 (en) 2017-08-15
SG190731A1 (en) 2013-07-31
EA027920B1 (ru) 2017-09-29
ES2567190T3 (es) 2016-04-20
PH12013501204A1 (en) 2013-07-29
DK2651436T3 (da) 2016-06-20
JP5951634B2 (ja) 2016-07-13
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
IL226448A (en) 2017-09-28
CY1122187T1 (el) 2020-11-25
HUE028452T2 (en) 2016-12-28
KR20130124525A (ko) 2013-11-14
EP3593813A1 (en) 2020-01-15
ZA201304015B (en) 2018-12-19
CA2819298A1 (en) 2012-06-21
CN103249431B (zh) 2016-11-02
EP2651437A1 (en) 2013-10-23
KR101951894B1 (ko) 2019-02-26
UY33802A (es) 2012-07-31
IL226448A0 (en) 2013-07-31
EP2651436B1 (en) 2016-03-30
UA110118C2 (uk) 2015-11-25
AU2011343368C1 (en) 2015-12-24
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
PL3023106T3 (pl) 2019-12-31
PH12013501203A1 (en) 2013-07-29
KR20140029376A (ko) 2014-03-10
EA201390630A1 (ru) 2013-12-30
US20130287809A1 (en) 2013-10-31
MX344706B (es) 2017-01-03
MY161412A (en) 2017-04-14
EP2651437B1 (en) 2016-02-10
DK3023106T3 (da) 2019-09-30
EP3023106A1 (en) 2016-05-25
SMT201600118B (it) 2016-07-01
EA027504B1 (ru) 2017-08-31
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
UA110806C2 (uk) 2016-02-25
AU2011343367B2 (en) 2015-05-21
PL2651437T3 (pl) 2016-07-29
HRP20191843T1 (hr) 2019-12-27
SI2651436T1 (sl) 2016-07-29
US20160220656A1 (en) 2016-08-04
SG190937A1 (en) 2013-07-31
TW201305192A (zh) 2013-02-01
CO6751287A2 (es) 2013-09-16
EP2651436A1 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
PH12013501204A1 (en) Mycobacterium antigenic composition
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
PH12013500467A1 (en) Pharmaceutical composition
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
GB201106750D0 (en) Novel compounds
WO2014145958A3 (en) Network-based microbial compositions and methods
MX349057B (es) Agente terapeutico que induce citotoxicidad.
PH12014501835A1 (en) Novel adjuvant compositions
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
IN2015DN02729A (es)
MY161601A (en) Films and compositions comprising the same
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BR112014013327A2 (pt) composições para cuidado oral
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
CY1117640T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA70225U (ru) Применение композиции, содержащей мирамистин, в качестве лекарственного средства для лечения заболеваний горла
TH143304A (th) องค์ประกอบก่อภูมิคุ้มกัน ซึ่งประกอบรวมด้วยแอนติเจนที่เกี่ยวข้องกับ m72
GB2515669A (en) Bacterial vaccine
UA52561U (ru) Применение пробиотиков как эзофагопротекторных и средств и средств для заживления язвы при неэрозивных поражениях пищевода
UA104138C2 (en) Novel adjuvant compositions
TH143305A (th) องค์ประกอบชนิดใหม่
GB201106340D0 (en) Composition

Legal Events

Date Code Title Description
FG Grant or registration